Product Details
| Product Name:
AZD0780 |
CAS No.:
2455427-91-3 |
| Purity:
98.56% |
Supply Ability:
10g |
| Release date:
2025/11/10 |
Product Introduction
Bioactivity
| Name | AZD0780 |
| Description | AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 247.5 mg/mL (597.23 mM), Sonication is recommended.
|
| Keywords | PCSK9 | EX-A-6975 | EX-A 6975 | AZD-0780 | AZD0780 | AZD 0780 |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Lipid Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:33005-95-7
$34.00 / 10mg
-
CAS:1140517-08-3
$123.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States